ESR(01821.HK)吐逾半成曾考驗配股價 股東趁高減持套逾43.3億元
遭股東趁高減持的ESR(01821.HK)市前合共有1.82億股以每股23.8元(較昨天收市價折讓6.3%)非自動對盤上板,涉資逾43.3億元。該股繼昨天高25.8元受制日前所造紀錄高位,今天股價曾回吐至23.8元配股價獲承接,現造24.05元,回吐5.3%,成交受配股上板帶動急增至2.023億股,涉資48.21億元。
ESR公布,股東WP OCIM與配售代理訂立配售協議,擬出售最少1.38億股持股。完成後,其持股量將減至不多於1.39億股或佔公司股本4.56%。同時,WP OCIM正與Laurels進行洽商,轉讓最多3.5億美元公司股份,也建議向Redwood提供作為買家參與出售機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.